XML 76 R35.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Collaborative Arrangements (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Collaborative Arrangements [Abstract] |
Collaborative Arrangements | Summarized financial information related to this collaboration is as follows:
Years Ended December 31 | 2024 |  | 2023 |  | 2022
Alliance revenue - Lynparza | $ | 1,311 |  |  | $ | 1,199 |  |  | $ | 1,116 |
Alliance revenue - Koselugo | 170 |  |  | 97 |  |  | 54 |
Total alliance revenue | $ | 1,481 |  |  | $ | 1,296 |  |  | $ | 1,170 |
Cost of sales (1) | 378 |  |  | 311 |  |  | 492 |
Selling, general and administrative | 165 |  |  | 192 |  |  | 185 |
Research and development | 77 |  |  | 79 |  |  | 106 |
December 31 | 2024 |  | 2023 |  |
Receivables from AstraZeneca included in Other current assets | $ | 424 |  |  | $ | 341 |  |  |
Payables to AstraZeneca included in Accrued and other current liabilities (2) | 713 |  |  | 256 |  |  |
Payables to AstraZeneca included in Other Noncurrent Liabilities (2) | — |  |  | 600 |  |  |
(1) Represents amortization of capitalized milestone payments. Amounts in 2024 and 2022 include $48 million and $250 million, respectively, of cumulative amortization catch-up expense as noted above. (2) Includes accrued milestone payments. Summarized financial information related to this collaboration is as follows:
Years Ended December 31 | 2024 |  | 2023 |  | 2022
Alliance revenue - Lenvima | $ | 1,010 |  |  | $ | 960 |  |  | $ | 876 |
Cost of sales (1) | 241 |  |  | 381 |  |  | 212 |
Selling, general and administrative | 159 |  |  | 189 |  |  | 158 |
Research and development | 21 |  |  | 66 |  |  | 136 |
December 31 | 2024 |  | 2023 |  |
Receivables from Eisai included in Other current assets | $ | 257 |  |  | $ | 226 |  |  |
Payables to Eisai included in Accrued and other current liabilities (2) | — |  |  | 125 |  |  |
(1) Represents amortization of capitalized milestone payments. Amount in 2023 includes $154 million of cumulative amortization catch-up expense as noted above. (2) Represents an accrued milestone payment. Summarized financial information related to this collaboration is as follows:
Years Ended December 31 | 2024 |  | 2023 |  | 2022
Alliance revenue - Adempas/Verquvo | $ | 415 |  |  | $ | 367 |  |  | $ | 341 |
Net sales of Adempas recorded by Merck | 287 |  |  | 255 |  |  | 238 |
Net sales of Verquvo recorded by Merck | 37 |  |  | 36 |  |  | 22 |
Total sales | $ | 739 |  |  | $ | 658 |  |  | $ | 601 |
Cost of sales (1) | 244 |  |  | 224 |  |  | 210 |
Selling, general and administrative | 111 |  |  | 131 |  |  | 153 |
Research and development | 102 |  |  | 90 |  |  | 75 |
December 31 | 2024 |  | 2023 |  |
Receivables from Bayer included in Other current assets | $ | 160 |  |  | $ | 156 |  |  |
Payables to Bayer included in Accrued and other current liabilities | 82 |  |  | 80 |  |  |
(1) Includes amortization of intangible assets, cost of products sold by Merck, as well as Bayer’s share of profits from sales in Merck’s marketing territories. Summarized financial information related to this collaboration is as follows:
Years Ended December 31 | 2024 |  | 2023 |  | 2022
Net sales of Lagevrio recorded by Merck | $ | 964 |  |  | $ | 1,428 |  |  | $ | 5,684 |
Cost of sales (1) | 554 |  |  | 852 |  |  | 3,038 |
Selling, general and administrative | 57 |  |  | 97 |  |  | 147 |
Research and development | 13 |  |  | 60 |  |  | 88 |
December 31 | 2024 |  | 2023 |  |
Payables to Ridgeback included in Accrued and other current liabilities (2) | $ | 68 |  |  | $ | 113 |  |  |
(1) Includes cost of products sold by Merck, Ridgeback’s share of profits, royalty expense, amortization of capitalized milestone payments and inventory reserves. (2) Includes accrued royalties. Summarized financial information related to this collaboration is as follows:
Years Ended December 31 | 2024 |  | 2023 |  |
Selling, general and administrative | $ | 26 |  |  | $ | 3 |  |  |
Research and development (1) | 351 |  |  | 5,549 |  |  |
December 31 | 2024 |  | 2023 |  |
Receivables from Daiichi Sankyo included in Other current assets | $ | 8 |  |  | $ | — |  |  |
Payables to Daiichi Sankyo included in Accrued and other current liabilities (2) | 817 |  |  | 800 |  |  |
Payables to Daiichi Sankyo included in Other Noncurrent Liabilities (2) | — |  |  | 750 |  |  |
(1) Expenses in 2023 include the $5.5 billion charge for the upfront and continuing option payments noted above. (2) Includes accrued continuation payment. Summarized financial information related to this collaboration is as follows:
Years Ended December 31 | 2024 |  | 2023 |  | 2022
Selling, general and administrative | $ | 16 |  |  | $ | 5 |  |  | $ | — |
Research and development (1) | 358 |  |  | 218 |  |  | 288 |
December 31 | 2024 |  | 2023 |  |
Payables to Moderna included in Accrued and other current liabilities | $ | 57 |  |  | $ | 63 |  |  |
(1) Expenses in 2022 include the $250 million option exercise payment noted above.

X
- Definition Collaborative Arrangements [Abstract] + References No definition available. + Details
Name: | mrk_CollaborativeArrangementsAbstract
Namespace Prefix: | mrk_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration